Gilead's Stock Rises 0.64% on Strong Earnings Despite CVS Coverage Hurdle Trading Volume Hits 146th

On August 20, 2025, Gilead Sciences (GILD) rose 0.64% to $117.57, with a trading volume of $640 million, ranking 146th in market activity. The stock’s performance was influenced by developments surrounding its HIV prevention drug Yeztugo and recent earnings results. CVS Health, a major U.S. insurer, announced it would not cover Yeztugo, potentially limiting the drug’s market reach. Despite this, Gilead reported strong Q2 earnings earlier in the month, driving a 7.3% surge in its shares. The company remains optimistic about securing coverage from 75% of U.S. insurers by year-end, mitigating some of the near-term risks.

The decision by CVS to exclude Yeztugo from its coverage list highlights ongoing challenges for Gilead in expanding access to its newer therapies. Yeztugo, a twice-yearly injectable HIV prevention treatment, faces competition and pricing scrutiny in a crowded market. However, the company’s broader HIV franchise continues to drive growth, supported by robust demand for its existing antiretroviral therapies. Analysts note that while insurer coverage delays could temporarily dampen sales, Gilead’s pipeline and diversified revenue streams offer resilience against short-term setbacks.

Gilead’s Q2 earnings underscored its ability to generate consistent revenue, with strong performance across its HIV and viral hepatitis portfolios. The company’s focus on long-acting therapies and its pipeline of innovative treatments position it to maintain market leadership. Despite the CVS exclusion, Gilead’s strategic emphasis on negotiating with other insurers and expanding global partnerships suggests a path to achieving its coverage targets. Investors remain cautious but are encouraged by the company’s operational execution and long-term growth prospects.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.